AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32487131
Drug: Placebo treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment: Identical margarine containing no added PS for 4 weeks.
Trial: 33739797
Drug: Sequential embryo
RxNorm normalized name: human embryo tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential embryo transfer on days 3 and 5
Trial: 33591115
Drug: NO‐NPO group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO‐NPO group (400 mL carbohydrate drink at midnight and freely up to 2 hours before anesthesia)
Trial: 33734121
Drug: Valsartan/Amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine combination (n=29)
Trial: 33734121
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS monotherapy (n=34)
Trial: 33087779
Drug: Se‐NPs (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se‐NPs (0.5 mg kg‐1) + RF (5 mg kg‐1)
Trial: 33087779
Drug: Se‐NPs (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se‐NPs (0.5 mg kg‐1) + RF (10 mg kg‐1)
Trial: 33087779
Drug: Se‐NPs (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se‐NPs (0.5 mg kg‐1) + RF (15 mg kg‐1)
Trial: 33087779
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (0 mg kg‐1 Se‐NPs + 0 mg kg‐1 RF)
Trial: 35998848
Drug: Selective endothelin-A
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective endothelin-A receptor antagonism
Trial: 35998848
Drug: Dual endothelin-A/B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual endothelin-A/B receptor blockade
Trial: 33166791
Drug: Nivolumab and
RxNorm normalized name: nivolumab and relatlimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab and ipilimumab (aPD‐1/aCTLA‐4) combination treatment
Trial: 33166791
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy (aPD‐1)
Trial: 32997182
Drug: Positive low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Positive low-dose computed tomography (LDCT)
Trial: 32997182
Drug: Indeterminate low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indeterminate low-dose computed tomography (LDCT)
Trial: 32997182
Drug: Negative low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Negative low-dose computed tomography (LDCT)
Trial: 34188004
Drug: Telmisartan, Ramipril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan, Ramipril, and their combination (exact dosages not specified)
Trial: 32388622
Drug: Oxytocin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (40 IU intranasal)
Trial: 33462883
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg) plus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) or carboplatin (AUC 6 mg/mL/min)
Trial: 33462883
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (PP arm)
Trial: 33462883
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus pemetrexed and platinum-based chemotherapy
Trial: 34728531
Drug: sitagliptin/metformin, insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin/metformin, insulin glargine and lifestyle therapy
Trial: 36188531
Drug: Light-sedation (L-Group)
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-sedation (L-Group) with bispectral index values kept in the range of 50–59
Trial: 36188531
Drug: Light-sedation (L-Group)
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light-sedation (L-Group)
Trial: 32354052
Drug: ICT-based health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICT-based health management services including respiratory and urinary care devices and home visit occupational therapy
Trial: 616864714
Drug: Albumin-bound paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin-bound paclitaxel (260 mg/m²) combined with pirarubicin (75 mg/m²)
Trial: 616864714
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m²) combined with pirarubicin (75 mg/m²)
Trial: 35614875
Drug: P2X3-receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: P2X3-receptor antagonist gefapixant
Trial: 34617561
Drug: FODMAPs (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FODMAPs (50 g/d)
Trial: 34617561
Drug: Gluten (17.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten (17.3 g/d)
Trial: 34616618
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of copra meal hydrolysate (CMH)
Trial: 34616618
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of copra meal hydrolysate (CMH)
Trial: 33957621
Drug: Amiloride 5
RxNorm normalized name: amiloride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 5 mg twice daily
Trial: 34172486
Drug: Whole-school sensitisation
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-school sensitisation (teacher-meetings and whole-school activities) (CC)
Trial: 35925755
Drug: Early diagnosis
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early diagnosis and rapid treatment allocation
Trial: 35413774
Drug: ACN-rich infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACN-rich infusion from aronia fruit (ARO)
Trial: 33829274
Drug: psychoeducation/cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: psychoeducation/cognitive behavioural therapy
Trial: 33829274
Drug: randomized treatment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: randomized treatment
Trial: 33829274
Drug: waiting more
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: waiting more than 4 months before starting treatment
Trial: 32247522
Drug: Perineural administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perineural administration of 40‐mg ketamine plus 0.375% ropivacaine in 40‐mL volume (Group RNK)
Trial: 32247522
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of 0.375% ropivacaine plus IV ketamine 40 mg (Group RIK)
Trial: 32247522
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of 0.375% ropivacaine (Group R)
Trial: 36173235
Drug: BP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP with fast-acting insulin aspart (BP-F), N=114
Trial: 36173235
Drug: BP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP with standard care insulin delivery (SC), N=54
Trial: 36173235
Drug: BP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP with aspart or lispro (BP-A/L), N=107
Trial: 33792623
Drug: Tislelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m2, day 1) and carboplatin (area under the concentration of 5, day 1)
Trial: 33792623
Drug: Tislelizumab plus
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab plus nab-paclitaxel (100 mg/m2, days 1, 8, and 15) and carboplatin
Trial: 39004848
Drug: Anti-psychotic medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-psychotic medications
Trial: 34175638
Drug: SAPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAPB with 30 ml of 0.5% ropivacaine
Trial: 36436481
Drug: Zafirlukast 10
RxNorm normalized name: zafirlukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast 10 mg BD for 10 days plus standard care
Trial: 33221027
Drug: Silexan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan 80 mg
Trial: 33221027
Drug: Silexan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan 80 mg/d (multiple dosing for 7 days)
Trial: 33221027
Drug: Silexan 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan 160 mg
Trial: 33221027
Drug: Silexan 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan 320 mg
Trial: 33591469
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravenous ZOL every 3 weeks for 1 year (17 total doses)
Trial: 35359478
Drug: Bilateral nasociliary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral nasociliary and maxillary nerve blocks with 12 mL of equal volumes of 0.5% bupivacaine and 2% lignocaine after induction of general anaesthesia
Trial: 36263451
Drug: Daily emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily emollient plus standard skin‐care advice
Trial: 33880760
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg orally alone
Trial: 33880760
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg i.v. infusion
Trial: 34514890
Drug: Goal-Focused Emotion-Regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goal-Focused Emotion-Regulation Therapy (GET)
Trial: 34514890
Drug: Individual Supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Supportive Therapy (ISP)
Trial: 36107179
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy + homeopathic protocol
Trial: 34941168
Drug: Ultrasound-guided quadratus
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided quadratus lumborum block (QLB) with 20 mL of 0.25% ropivacaine on each side
Trial: 32111521
Drug: Brazil nut
RxNorm normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazil nut supplementation (one unit daily for 3 months)
Trial: 34774185
Drug: IVIG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (2 g/kg over 4 days)
Trial: 33217092
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor (SGLT2i)
Trial: 33685306
Drug: Glucocorticoid (GC)
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (GC) injection
Trial: 33130890
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) chemotherapy
Trial: 39111544
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) therapy
Trial: 32846806
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no NHF therapy)
Trial: 35137345
Drug: Ovitrelle® (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovitrelle® (250 µg; 6500 IU)
Trial: 33333105
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake ≥232 mg/day
Trial: 33333105
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake >480 mg/day
Trial: 33333105
Drug: Caffeine intake
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine intake ≥321 mg/day
Trial: 35039263
Drug: Kangfuyan capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangfuyan capsule combined with antibiotics (azithromycin + metronidazole)
Trial: 35039263
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (azithromycin + metronidazole) alone (control group)
Trial: 32130164
Drug: Medication Ambient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Ambient Display (MAD)
Trial: 34475873
Drug: Nasal Foralumab
RxNorm normalized name: Foralumab
DrugBank: Foralumab (DB16170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Foralumab (100ug/day) given for 10 consecutive days with 6 mg dexamethasone given on days 1-3 (n=11)
Trial: 34475873
Drug: Foralumab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foralumab treatment
Trial: 32933953
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural treatment for insomnia (CBT‐I) for 8 weeks plus 4 bimonthly booster sessions
Trial: 33306114
Drug: Social norm
RxNorm normalized name: K Norm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social norm email feedback program (2 emails with evidence-based information about nimodipine and individual prescription levels)
Trial: 33306114
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (opened emails)
Trial: 35863486
Drug: Tobramycin Inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin Inhalation Solution (300 mg/5 ml twice daily)
Trial: 35863486
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline 5 ml twice daily)
Trial: 33347814
Drug: PARP inhibitors
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitors
Trial: 32134291
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy adapted for patients with IBS (MBCT-IBS)
Trial: 33030515
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2, days 1, 8, and 15 every 4 weeks)
Trial: 33030515
Drug: Paclitaxel with
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel with Bevacizumab (10 mg/kg, every 2 weeks for 6 cycles, followed by maintenance bevacizumab 15 mg/kg every 3 weeks)
Trial: 35894080
Drug: Liraglutide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3 mg subcutaneously daily)
Trial: 33247483
Drug: Citalopram (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (up to 40 mg/day) plus Tipepidine (30 mg twice daily)
Trial: 33247483
Drug: Citalopram (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (up to 40 mg/day) plus Placebo
Trial: 32272022
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - budesonide
Trial: 33752439
Drug: Early rule-out
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rule-out pathway using high-sensitivity cardiac troponin I concentrations <5 ng/L at presentation.
Trial: 32960309
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment of Lisfranc injuries
Trial: 32815804
Drug: ISBPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISBPB with 20 cc of 0.25% levobupivacaine + 3.3 mg dexamethasone (group LD)
Trial: 32815804
Drug: ISBPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISBPB with 20 cc of 0.25% levobupivacaine (group L)
Trial: 32683388
Drug: Polytetrafluoroethylene (PTFE)
RxNorm normalized name: polytetrafluoroethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polytetrafluoroethylene (PTFE) strips as an adjunct to epinephrine impregnated gauze
Trial: 34036728
Drug: Multimicronutrient‐fortified lipid‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimicronutrient‐fortified lipid‐based nutrient supplement containing 250‐μg I per day started immediately after randomization (Arm 1)
Trial: 34036728
Drug: Multimicronutrient‐fortified lipid‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimicronutrient‐fortified lipid‐based nutrient supplement containing 250‐μg I per day started at 12 weeks gestation (Arm 2)
Trial: 34036728
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention supplement (Arm 3)
Trial: 35849009
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (3.5 g) of EPA + DHA
Trial: 35849009
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (2.0 g) of EPA + DHA
Trial: 34254892
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behaviour therapy for perfectionism (ICBT-P)
Trial: 34254892
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (access to treatment 8 weeks post-randomisation)
Trial: 35266378
Drug: Ultrasound-guided serratus
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided serratus plane block (SPB) with 30 mL 0.25% bupivacaine
Trial: 35266378
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 2 mL saline injection subcutaneously
Trial: 34932077
Drug: Proactive therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive therapeutic drug monitoring (TDM) with dose and interval adjustments based on scheduled monitoring of serum drug levels and antidrug antibodies (n=228)
Trial: 34932077
Drug: Standard infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard infliximab therapy without drug and antibody level monitoring (n=230)
Trial: 35121062
Drug: Yerba mate
RxNorm normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yerba mate infusion (300 mL)
Trial: 35121062
Drug: Hot tea
RxNorm normalized name: ChoreMate One-Shot Teat Dip 1 % (titratable iodine concentrate 3.6 % ) Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot tea (300 mL)
Trial: 35121062
Drug: Cold tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold tea (300 mL)
Trial: 35121062
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of hot tea and yerba mate infusion
Trial: 32408846
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) for 8 weeks
Trial: 36502333
Drug: M. officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. officinalis extract (500 mg of RA per day)
Trial: 34478124
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI; Acthar® Gel) 80 U subcutaneously every other day for 4 weeks and then twice weekly through week 24
Trial: 34478124
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI; Acthar® Gel)
Trial: 36369781
Drug: Ultrasound-guided genicular
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided genicular nerve block (GNB) with 5.7 mg celestone chronodose (1 ml) and 0.5% bupivacaine (3 ml)
Trial: 33952684
Drug: Obturator nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obturator nerve block with 20 mL of ropivacaine 0.2%
Trial: 32701129
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus radiotherapy (IMRT after chemotherapy)
Trial: 34724405
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) intervention teaching pain self‐management skills in 12 weekly, 90‐minute groups delivered by an interdisciplinary team.
Trial: 34553395
Drug: GSH-FBT (online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSH-FBT (online guided self-help family-based treatment) for parents, 12 sessions of 20 minutes each
Trial: 34553395
Drug: FBT-V (family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBT-V (family-based treatment delivered via videoconferencing), 15 sessions of 60 minutes each
Trial: 33067703
Drug: Carboplatin (AUC5)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC5) and bevacizumab (10 mg/kg) every 3 weeks